Cancer treatment in China costs 50-85% less than in the US across surgery, chemotherapy, radiation, proton therapy, immunotherapy, and CAR-T. Real hospital pricing and data for 2026.
Cancer treatment china cost runs 50-85% below US pricing across every treatment modality: surgery, chemotherapy, radiation, proton therapy, immunotherapy, and CAR-T. A full course of proton therapy that costs $100,000-$150,000 in the US is $38,000-$55,000 at the Shanghai Proton and Heavy Ion Center, according to published hospital fee schedules. Per-cycle immunotherapy (PD-1 inhibitors) costs $1,500-$3,000 in China versus $10,000-$15,000 in the US. And China's cancer hospitals are among the highest-volume in the world: Fudan University Shanghai Cancer Center alone treats over 80,000 patients annually.
Prices and statistics current as of March 2026.
Treatment | US Cost | China Cost | Savings |
|---|---|---|---|
Surgery | |||
Lung lobectomy | $40,000-$80,000 | $10,000-$20,000 | 50-75% |
Mastectomy + reconstruction | $30,000-$60,000 | $8,000-$15,000 | 50-75% |
Liver resection (partial hepatectomy) | $50,000-$100,000 | $12,000-$25,000 | 50-75% |
Radical prostatectomy (robotic) | $25,000-$45,000 | $8,000-$16,000 | 56-64% |
Thyroidectomy | $10,000-$25,000 | $3,000-$6,000 | 60-76% |
Chemotherapy | |||
Standard chemo (per cycle) | $5,000-$15,000 | $1,000-$3,000 | 67-80% |
Full 6-cycle regimen | $30,000-$90,000 | $6,000-$18,000 | 67-80% |
Radiation | |||
IMRT (full course, 30-35 sessions) | $30,000-$60,000 | $8,000-$15,000 | 50-75% |
Proton therapy (full course) | $100,000-$150,000 | $38,000-$55,000 | 45-63% |
Heavy ion therapy (carbon ion) | $140,000-$200,000 | $50,000-$70,000 | 50-65% |
Immunotherapy | |||
PD-1 inhibitor (per cycle) | $10,000-$15,000 | $1,500-$3,000 | 70-85% |
Full immunotherapy course (12 cycles) | $120,000-$180,000 | $18,000-$36,000 | 70-80% |
CAR-T Cell Therapy | |||
CAR-T (all-in) | $488,000-$760,000 | $50,000-$80,000 | 84-90% |
These aren't theoretical numbers. They reflect published hospital fee schedules, OECD health expenditure data (opens in new tab), and pricing from China's National Healthcare Security Administration. For a detailed breakdown of CAR-T pricing, see our guide to CAR-T therapy cost in China.
Proton and heavy ion therapy in China costs $38,000-$70,000, compared to $100,000-$200,000 in the US. The Shanghai Proton and Heavy Ion Center (SPHIC) opened in 2015 and has treated over 6,000 patients. Published outcomes from SPHIC include:
Nasopharyngeal carcinoma: Five-year overall survival of 92.9% with carbon ion therapy, per a 2023 study in the International Journal of Radiation Oncology, Biology, Physics (opens in new tab)
Skull base chordoma: Three-year local control rate exceeding 85%
Prostate cancer: Outcomes comparable to the top proton centers in the US and Japan, with significantly fewer gastrointestinal side effects compared to conventional radiation
China currently has 10 proton/heavy ion therapy centers operating, with over 60 additional centers planned or under construction through 2030, according to the Chinese Society of Radiation Oncology. The US has 44 proton centers, but wait times can stretch 4-8 weeks at popular facilities like MD Anderson or Mayo Clinic. Several Chinese centers have shorter wait times because capacity is expanding faster than demand.
The cost difference is staggering. A full proton therapy course runs $100,000-$150,000 in the US. At SPHIC, the same treatment runs $38,000-$55,000. And SPHIC's published survival data is in the same range as Memorial Sloan Kettering and MD Anderson.
Heavy ion (carbon ion) therapy is even rarer globally. Only six countries operate carbon ion centers: Japan, Germany, Austria, Italy, China, and South Korea. The US has zero. If your oncologist recommends carbon ion therapy, China and Japan are essentially your only practical options, and China is significantly cheaper. Learn more about planning a medical trip to China.
Immunotherapy in China costs $1,500-$3,000 per cycle versus $10,000-$15,000 in the US, and China has approved both international PD-1/PD-L1 inhibitors and domestically developed alternatives.
International products available in China: pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), durvalumab (Imfinzi). These are the same drugs used in US hospitals.
Chinese-developed checkpoint inhibitors: sintilimab (Tyvyt, by Innovent), tislelizumab (by BeiGene), camrelizumab (by Hengrui), and toripalimab (by Junshi). These target the same PD-1 pathway, have published phase 3 data in international journals, and are NMPA-approved for multiple cancer types.
The price difference is dramatic. A single cycle of pembrolizumab costs $10,000-$15,000 in the US. Sintilimab, with comparable published efficacy data for non-small cell lung cancer, costs roughly $1,500-$2,500 per cycle in China. Over a standard 12-cycle course, that's $18,000-$30,000 versus $120,000-$180,000.
A 2022 meta-analysis published in The Lancet Oncology (opens in new tab) compared Chinese domestic PD-1 inhibitors head-to-head with pembrolizumab and nivolumab in NSCLC. Progression-free survival and overall response rates were statistically comparable. Dr. Yi-Long Wu, MD, a thoracic oncologist at Guangdong Lung Cancer Institute and co-chair of the IASLC, has noted: "Chinese-developed PD-1 inhibitors have demonstrated non-inferior efficacy to imported agents in randomized phase 3 trials, fundamentally changing the cost-access equation for patients across Asia." The drugs aren't identical molecules, but they work through the same mechanism and produce similar clinical outcomes. For a deeper look at immunotherapy options, read our guide to immunotherapy cost in China.
China's top cancer hospitals treat hundreds of thousands of patients per year and publish in the same journals as US institutions. The five centers below accept international patients.
Fudan University Shanghai Cancer Center. Over 80,000 patients treated annually. Ranked highest in China for oncology. Strong programs in breast, lung, colorectal, and head/neck cancers. International patient department with bilingual coordinators. Published extensively in The Lancet Oncology, Journal of Clinical Oncology, and Annals of Oncology.
Peking University Cancer Hospital, Beijing. Home to one of China's most active CAR-T programs and a leader in GI oncology. Dr. Jun Zhu, MD, PhD, a globally recognized lymphoma researcher, leads the hematology division. International department handles English-speaking patients.
Sun Yat-sen University Cancer Center, Guangzhou. Particularly strong in nasopharyngeal carcinoma (NPC), a cancer far more common in southern China. Their NPC outcomes data is among the best published globally. SPHIC refers NPC patients here for combined treatment approaches.
Shanghai Proton and Heavy Ion Center (SPHIC). Not a full-service cancer hospital, but the primary proton/heavy ion facility in China and one of the most advanced globally. Treats skull base, head/neck, lung, liver, prostate, and pediatric cancers.
Tiantan Hospital, Beijing. China's top neurosurgery center and the best option for brain tumors. Over 10,000 cranial surgeries annually. Published outcomes for glioma resection comparable to Western centers.
Each hospital has an international patient department. You send your records, they review your case, and they provide a treatment plan with cost estimate before you make any travel decisions. You can also browse oncology procedures and pricing on Sylk Health or connect with a specialist directly.
Treatment planning for international patients follows a structured 7-step process, typically taking 3-6 weeks from initial inquiry to treatment start.
Remote records review. Email your pathology reports, imaging (CT, MRI, PET), prior treatment history, and current medications to the hospital's international department. Allow 1-2 weeks for review.
Tumor board consultation. Your case is reviewed by a multidisciplinary team: surgeon, medical oncologist, radiation oncologist, pathologist. You receive a proposed treatment plan with timeline and cost estimate.
Decision and scheduling. You review the plan with your US oncologist, ask questions via email or video call, and confirm your intention to proceed. The hospital schedules your arrival date.
Travel and arrival. Fly to China. The international department typically arranges airport pickup and hotel recommendations.
On-site evaluation. Additional testing as needed, often a repeat biopsy, updated imaging, cardiac clearance. Treatment begins within 3-7 days of arrival.
Treatment. Duration depends on modality: surgery (1-2 weeks), chemotherapy (varies by regimen), radiation (5-7 weeks), CAR-T (8-10 weeks).
Discharge and follow-up plan. You receive a translated discharge summary, imaging, pathology, and a follow-up schedule your US oncologist can follow. Telemedicine check-ins available.
The entire process, from initial inquiry to treatment start, typically takes 3-6 weeks. For urgent cases, some hospitals can expedite to 1-2 weeks.
Clinical trials in China numbered over 1,200 active cancer studies recruiting patients in 2024, more than any other country according to ClinicalTrials.gov (opens in new tab) data. Dr. Jie He, MD, FACS, president of the National Cancer Center of China and a thoracic surgeon, has observed: "China's scale of clinical trial enrollment now rivals the United States, giving patients access to investigational therapies across every major tumor type." Categories include:
CAR-T targeting solid tumors (liver, gastric, pancreatic)
Bispecific antibodies for lymphoma and myeloma
Combination immunotherapy regimens not yet available in the US
Novel radiation sensitizers paired with proton therapy
TCM integration studies for chemotherapy side effect management
Some trials accept international participants. If standard treatment options have been exhausted, ask the hospital's international department about trial eligibility. Access to experimental therapy that hasn't reached the US yet is a genuine advantage of Chinese cancer care. See our overview of medical tourism savings for additional context on cost comparisons.
Total cost scenarios below show savings ranging from $55,000 to $686,000 depending on the treatment modality, based on published hospital fee schedules.
Scenario 1: Early-stage lung cancer (surgery + adjuvant chemo)
Lobectomy: $12,000
4 cycles adjuvant chemo: $6,000
Hospital stay + follow-up: $3,000
Travel and accommodation (4 weeks): $4,000
China total: ~$25,000 vs. US total: $80,000-$140,000
Scenario 2: Head/neck cancer (proton therapy)
Proton therapy (30 fractions): $45,000
Pre-treatment evaluation: $2,000
Travel and accommodation (7 weeks): $6,500
China total: ~$53,500 vs. US total: $130,000-$180,000
Scenario 3: Relapsed lymphoma (CAR-T)
CAR-T therapy (all-in medical): $65,000
Travel and accommodation (10 weeks): $9,000
China total: ~$74,000 vs. US total: $500,000-$760,000
The savings in Scenario 3 alone could fund a child's college education. That's not an abstraction. For families dealing with relapsed cancer, these are real financial calculations that affect real lives.
Yes, China's top cancer hospitals treat every major cancer type. Fudan University Shanghai Cancer Center alone handles over 80,000 cases annually across lung, breast, colorectal, liver, gastric, pancreatic, prostate, blood cancers, brain tumors, and head/neck cancers, according to their published annual reports. The key question is whether a hospital's particular expertise matches your case. Send your records to 2-3 hospitals and compare their proposed treatment approaches. Each hospital's international department provides case evaluations within 1-2 weeks.
Email the hospital's international patient department directly. Most departments respond within 3-5 business days, according to published intake timelines from Fudan University Shanghai Cancer Center. You will need: pathology report (including molecular markers if available), recent imaging (CT, MRI, PET in DICOM format preferred), treatment history summary, and current medication list. Hospitals provide a secure upload portal or accept encrypted email attachments. Most accept medical records in English without requiring translation.
You complete the full radiation course in China, typically 5-7 weeks for 30-35 sessions. After returning home, your US oncologist handles follow-up imaging, bloodwork, and monitoring using the treatment plan, dose maps, and follow-up protocol provided by your Chinese team. Any US radiation oncologist can interpret this data, since radiation physics and reporting standards follow international guidelines set by the International Commission on Radiation Units. The Chinese team remains available for telemedicine consultations as needed.
Yes, for international standard regimens the drugs are identical. Protocols like FOLFOX, FOLFIRINOX, R-CHOP, and AC-T use the same molecules manufactured by the same global pharmaceutical companies or biosimilar equivalents approved by China's NMPA. A 2022 meta-analysis in The Lancet Oncology confirmed comparable efficacy between Chinese-approved biosimilars and originator drugs. For domestically developed drugs (like sintilimab vs. pembrolizumab), the molecules differ but target the same pathways with similar published response rates across phase 3 trials.
Stay duration depends entirely on treatment type. Surgery requires 2-3 weeks in China. Chemotherapy varies by regimen, with each cycle taking a few days and 2-3 week gaps between cycles (some patients fly home between cycles). Radiation and proton therapy require 6-8 weeks for a full course of 30-35 sessions, per standard protocols from SPHIC. CAR-T therapy requires 8-10 weeks. Your Chinese hospital provides a detailed timeline before you travel so you can plan accordingly.
Cancer recurrence is managed the same way regardless of where initial treatment occurred. Your US oncologist takes over using the full treatment record from China, including pathology, imaging, dose records, and follow-up protocols. According to guidelines from the National Comprehensive Cancer Network (NCCN), recurrence workup follows standardized international protocols. If a second course of treatment in China makes financial or medical sense, the Chinese hospital's international department can expedite re-evaluation, often within 1-2 weeks.
No one should have to choose between effective cancer treatment and financial survival. But in the US, that's the reality for thousands of families every year. The cancer treatment cost in China doesn't eliminate the disease, but it eliminates one of the biggest barriers to fighting it.
Same hospitals publishing in The Lancet. Same drugs approved by a national regulator. Published survival data in the same range. At 50-85% less.
If you're facing a cancer diagnosis and the US price is part of the problem, look at the numbers.
Explore oncology procedures and pricing →
This article is for informational purposes only and does not constitute medical advice. Cancer treatment decisions should be made in consultation with your oncologist. Costs are estimates based on published data and hospital fee schedules; actual costs vary by cancer type, stage, and treatment plan.
Connect with world-class healthcare providers and explore treatment options tailored to your needs.
Expert network
Top providers worldwide
Verified credentials
Quality assured
Transparent pricing
Compare costs
